- Issues relating to the labeling of generic drugs. - Issues relating to the 180 day exclusivity for generics. - Issues related to medical supply chain, including supply chain safety. - Issues related to drug pricing including drug negotiation. - Issues related to Inflation Reduction Act.
2025 · 3rd Quarter (July 1 - Sep 30)
ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY GENERIC PHARMACEUTICAL ASSOC.)
Filed by CAPITOL HILL CONSULTING GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- CAPITOL HILL CONSULTING GROUP
- Filing UUID
- 5f6a6620-ea3a-45e9-927c-4c343e7d432b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to the cost of prescription drugs. Issues pertaining to coverage and reimbursement of biosimilars. Issues related to Part D coverage of generic drugs, including Part D redesign. Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars. Issues related to Medicare Part D reform. Issues related to drug shortages
Issues related to potential tariffs on generic drugs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.